Tag Archive for: ADCs

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

New deal builds on encouraging preliminary clinical data from the Phase 1 study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021 The expanded collaboration to provide Innovent with access to additional targets and further proprietary Synaffix linker-payloads for the development of additional innovative ADCs  Synaffix will be eligible to […]

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer

Dr. Yang brings extensive experience in leading early-stage clinical trials and late stage global registrational trials London UK / Cambridge, MA USA, 10 October 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, […]

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

Newly appointed CEO has over 20 years’ experience in company building and strategic business development London UK / Cambridge, MA USA, 25 July 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive […]

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesenas Chief Medical Officer

Dr. Ottesen brings in-depth global clinical development expertise in oncology, including biologics, small molecules, immunotherapies and ADCs Adcendo further builds its world class team to accelerate development of lead ADC asset uPARAP and to expand its first-in-class ADC pipeline Copenhagen, Denmark, June 20, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of […]

Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, […]